Colossal Biosciences

Colossal Biosciences is a biotechnology and conservation company founded by Ben Lamm and geneticist Dr. George Church. The company utilizes a modular scientific toolkit—combining CRISPR gene editing, ancient DNA science, synthetic biology, and advanced computing—to resurrect extinct species, including the woolly mammoth, Tasmanian tiger, dodo bird, and dire wolf. Rather than simple cloning, Colossal’s approach focuses on engineering organisms that are genetically similar to extinct species, incorporating core genes that enhance adaptability and resilience for modern environments. The company operates at the intersection of genetics and conservation, aiming to restore lost biodiversity and develop technologies that can also be applied to protect at-risk, living species.

Colossal’s work has significant implications for global conservation efforts and biotechnology. By developing tools like artificial wombs and large-scale biobanking, such as its collaboration with the United Arab Emirates to create a global network of biovaults, the company provides resources for preserving genomic data and supporting endangered species. While its ambitious de-extinction goals generate both scientific excitement and ethical debate, the technologies developed in its labs have potential commercial applications in fields like fertility medicine and environmental management. Colossal, which has achieved significant venture capital backing and valuation, operates a private, research-intensive model that focuses on long-term ecological restoration and the creation of a biological back-up plan for the planet’s biodiversity.